> ## Content Index > Fetch the complete content index at: https://nexi.fund/llms.txt > Use this file to discover other available public pages before exploring further. # AI-Designed Enzymes Just Brought Manufacturing Outside the Cell - URL: https://nexi.fund/ai-enzyme-cellfree-biomanufacturing-2026/ - Published: 2026-09-07T11:00:03.000Z - Updated: 2026-09-07T11:00:03.000Z - Description: Cell-free biomanufacturing crossed from lab to industrial pilot in 18 months. Four companies carry the commercial thesis. - Author: Nexi.fund Labs - Tags: Biotech & Health, #mode-1, #hook-statistic, #track-F Two hundred liters of hyaluronic acid, made without a single living cell. That pilot run, completed in late 2025 by Israeli biotech Enzymit with Dutch cooperative Cosun, is the first scaled proof that the cell itself is no longer the bottleneck in biomanufacturing. Enzymes designed by AI, running outside any organism, produced multi-kilogram batches of the molecule used in dermal fillers, wound care and drug delivery. The maker chooses the polymer size by dial, not by rewriting a genome. 🎯 Cell-free biomanufacturing crossed from lab demonstration to industrial pilot in the last 18 months, carried by AI-designed enzymes. The hyaluronic acid market alone is worth $9.4 billion today and is projected to reach $15.9 billion by 2035\. That is a large, high-purity demand base for the first scaled process. A public-market signal arrived in August 2026: eXoZymes, the Nasdaq-listed cell-free platform, reported quarterly results as its pilot-scale runs with Cayman Chemical moved toward commercial economics. The investment question is no longer whether enzymes can replace cells. It is which companies hold proprietary enzyme libraries and which scale-up economics will hold. The field had promised this before. Enzyme engineering has spent two decades as a story about tomorrow: bio-based chemicals cheaper than petroleum, made in gentle reactors instead of cracking towers. The promise was real and the delivery kept slipping, because designing a useful enzyme took years of directed evolution in the lab. AI changed the design loop, and cell-free production changed the economics that follow. ## The cell was the constraint all along Industrial fermentation works. It also carries limits baked into biology. A microbe spends carbon on staying alive before it spends any on your product. Toxic compounds accumulate and kill the batch. A strain that behaves in a 10-liter flask needs years of re-engineering to survive a 100,000-liter tank. Cell-free systems remove those constraints by construction: enzymes extracted from their host and run in solution, with the pathway engineered around the product instead of around the organism's survival. 200 L cell-free HA pilot #### Enzymit–Cosun pilot scale, Nov 2025 First scaled run of enzyme-only hyaluronic acid production, using AI-designed enzymes outside living cells. · *PR Newswire, 2025* The pilot run matters less for its size than for what it controls. The same enzymatic process produces hyaluronic acid from roughly 10 kilodaltons to 4 megadaltons with a narrow size distribution, adjusted through standard production settings rather than by engineering a new organism. In cell-based manufacturing, molecular weight is a property you inherit from the strain. In a cell-free system it becomes a process parameter, which is a different kind of industrial asset. #### Why drop the cell? Carbon efficiency: no biomass, so more of the feedstock becomes product. Faster design cycles: the pathway is assembled and tested in days, not re-engineered over years. Cleaner output: fewer living contaminants, less downstream purification. The trade-off is the cost of the catalysts themselves: enzymes must be made, stabilized and recycled at industrial scale. ## The players with proprietary enzymes Four companies carry the near-term commercial thesis, and they divide the field in instructive ways. Enzymit (backed by Khosla Ventures and Grove Ventures) owns the scaled cell-free process proof. Scindo in London sells cell-free routes to ingredients for flavors, fragrances and cosmetics, and counts a food major's venture arm among its investors. eXoZymes, listed on Nasdaq, is the market's liquid bet on cell-free natural products. Arzeda in Seattle leads a $7.8 million US National Science Foundation consortium on electricity-driven enzyme cascades. > This isn't just a breakthrough in hyaluronic acid production — it's a glimpse into the future of how we make molecules. We've proven that precision manufacturing of biomolecules is no longer limited by what cells can or can't do.— Gideon Lapidoth, CEO, Enzymit Scindo, founded in 2020 by Gustaf Hemberg, Ben Davis and Juliet Sword, raised £4 million in seed funding co-led by Kadmos Capital and Clay Capital, with participation from PINC, the venture arm of Paulig. The company maps enzyme functions that traditional chemistry struggles with, carbon-hydrogen activations and carbon-carbon bond cleavages, and converts renewable feedstocks directly into ingredients. Two products, one for flavor molecules and one for cosmetics, sit near pilot scale, and both rely on the same cell-free logic as Enzymit's process. $9.4B HA market, 2025 #### Hyaluronic acid products Global market valued at $9.43B in 2025, projected to $15.94B by 2035\. High-purity grades are the cell-free opportunity. · *PR Newswire, 2025* The investment logic differs across the four. Enzymit and Scindo are private, venture-backed bets on process economics. eXoZymes gives an investor direct exposure through public equity: its Q2 2026 report in August confirmed pilot-scale runs with Cayman Chemical and a collaboration with Lawrence Berkeley National Laboratory on AI-driven digital twins of enzyme manufacturing, funded at roughly $747,000\. Management reported taking a molecule from concept to pilot validation within two years. Arzeda's angle is the furthest from market and the closest to a step change. Its NSF consortium, run with Missouri University of Science and Technology and Novonesis, targets electricity-driven enzyme cascades that convert carbon dioxide into methanol, aiming above 70% energy efficiency against losses of more than 50% typical of chemical electrocatalysis. If cell-free manufacturing removes the organism, electricity removes the feedstock. CO₂ becomes the input. > With AI-designed enzymes that run directly on electrons, we can bypass many limitations of living cells and build cleaner, more efficient routes for difficult-to-synthesize critical chemicals like methanol.— Alexandre Zanghellini, CEO, Arzeda ## Why the economics shifted Two costs fell simultaneously. AI compressed the enzyme design cycle from years to weeks, and gene synthesis plus high-throughput screening got an order of magnitude cheaper. That combination is what makes cell-free production viable as a business rather than a laboratory curiosity: the enzyme is now cheap enough to design, make and recycle at industrial volume. Scindo's investor framing makes the market logic explicit. The specialty chemicals industry still leans on petroleum derivatives for flavors, fragrances and cosmetic ingredients. The alternative is an enzyme that performs the same transformation on renewable or waste carbon. Clay Capital partner Ali Morrow described the approach as designing molecular craftsmen, enzymes built for specific industrial jobs that unlock feedstocks the petrochemical route cannot use. > Scindo's approach creates molecular craftsmen — enzymes designed for specific industrial jobs that offer cost-competitive natural alternatives and unlock previously inaccessible feedstocks, creating significant opportunities globally to end the industry's reliance on crude oil.— Ali Morrow, Partner, Clay Capital The addressable prize is large. The specialty chemicals and ingredients industry still sources flavors, fragrances and cosmetic components from petroleum. Enzymes touch only a sliver of that value chain today. As we wrote in August, when LanzaTech pushed carbon recycling toward a commercial ethanol barge, the pattern repeated: a process that works at pilot scale only becomes an investment thesis once a plant runs continuous shifts. Industry market research points to 50–70% energy savings and 40–60% water savings from enzyme-based processes against conventional chemistry. Those are the kind of numbers that eventually move procurement decisions, not just laboratory budgets. #### What the public market says eXoZymes trades on Nasdaq and reported Q2 2026 results on 20 August: pilot validation with Cayman Chemical and an AI digital-twin project with Lawrence Berkeley National Laboratory. Its stated thesis: eliminating the scaling bottleneck that has limited commercial synthetic biology. CEO Michael Heltzen cited a molecule moved from concept to pilot validation and past original commercial economic targets in under two years. ## The history of enzyme promises argues for caution None of this is guaranteed to scale. Cell-free production has carried a cost problem since its academic origins: purified enzymes and cofactors are expensive, and running a pathway for long enough to be economic demands stability that natural enzymes do not always deliver. Twenty years of bio-based chemical announcements that did not reach commercial volume are a standing reminder that pilot success and plant economics are different things. The competing startups illustrate the technical risk too. Manchester's Imperagen combines quantum-physics simulation with AI and robotic labs to report 500-fold enzyme improvements across five cycles. Biomatter in Lithuania built its generative platform on a protein GAN and lists Thermo Fisher Scientific, BASF and Kirin as partners. Cradle works with Novonesis, Bayer and Lundbeck. A field with this many credible players usually means the technology works and the differentiation is still to be proven. ### What happens to cell-free biomanufacturing a year from now? 🔮 **By late 2027, at least two cell-free products will be in commercial production, and the first will be a high-purity cosmetic or pharma ingredient rather than a commodity chemical.** Probability: 65%. Pilot economics at Enzymit and Scindo are the closest to plant handoff, and high-margin ingredients tolerate enzyme costs that commodity chemicals cannot. #### ✅ Arguments for Scindo already has two products near pilot scale and food-industry backing from Paulig's PINC. eXoZymes reports passing its own commercial economic targets at pilot scale. **Confirmation criteria:** a named commercial supply contract, or first revenue disclosed by Enzymit, Scindo or eXoZymes by end of 2027\. #### ❌ Arguments against Enzyme cost and stability at sustained production runs remain the known blockers. The industry's history of bio-based chemical scale-ups that stalled at pilot is long. **Disconfirmation criteria:** a second consecutive year without a commercial plant, or a major partner quietly dropping a cell-free program. 📊 **Key signals to track** First commercial supply contract announced by Enzymit, Scindo or eXoZymes Arzeda's NSF consortium moving from electrochemistry demonstration to continuous operation A major fragrance or cosmetics house signing a cell-free offtake Enzyme unit cost disclosures in any company's reporting ### Development scenarios #### 🟢 Optimistic scenario (30%) Enzyme costs keep falling with AI design loops; two or more cell-free products reach commercial revenue and cosmetic majors sign multi-year offtakes. **Implications:** private leaders become acquisition targets for ingredient conglomerates, and cell-free valuation premiums apply across the field. #### 🟡 Base-case scenario (50%) One high-value ingredient reaches commercial scale; cell-free remains niche inside a broadly fermentation-based industry. **Implications:** the winners are the companies with proprietary enzymes and contracts, and the field consolidates rather than displaces. #### 🔴 Pessimistic scenario (20%) Enzyme stability and cost block sustained production; the field repeats the pattern of bio-based scale-up failures from prior decades. **Implications:** capital rotates out of cell-free startups, and eXoZymes trades down to its cash position. ## Sources [ Enzymit Achieves World's First Scaled Cell-Free Production of Hyaluronic Acid Primary account of the 200-liter pilot run with Cosun, including molecular-weight control from 10 kDa to 4 MDa. SynBioBeta ](https://www.synbiobeta.com/read/enzymit-and-cosun-have-successfully-pioneered-the-production-of-high-purity-hyaluronic-acid-through-a-novel-cell-free-biomanufacturing-process?ref=nexi.fund) The key evidence that cell-free production works at pilot scale. [ Arzeda to Lead NSF-Funded Initiative for Electricity-Driven Cell-Free Biomanufacturing The $7.8 million NSF CFIRE award for CO₂-to-methanol enzyme cascades, with Novonesis and Missouri S&T. PR Newswire ](https://www.prnewswire.com/news-releases/arzeda-to-lead-major-nsf-funded-initiative-advancing-electricity-driven-cell-free-biomanufacturing-through-ai-designed-enzymes-302570780.html?ref=nexi.fund) Evidence the field is moving toward feedstock-free manufacturing. [ eXoZymes Reports Second Quarter 2026 Results and Provides Business Update The public-market signal: quarterly results for the cell-free platform and its AI-enhanced enzymes. Newswire ](https://www.newswire.com/view/content/exozymes-reports-second-quarter-2026-results-and-provides-business-update-at?ref=nexi.fund) The freshest anchor for the commercial inflection argument. [ Enzymit Achieves the World's First Scaled Cell-Free Production of Hyaluronic Acid Investor-side commentary from Enzymit backer Grove Ventures on the milestone's significance. Grove Ventures ](https://www.grovevc.com/news/enzymit-achieves-the-worlds-first-scaled-cell-free-production-of-hyaluronic-acid?ref=nexi.fund) Adds the investor view on why the milestone matters. [ Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes Technology Independent pilot validation of the exozyme platform with a commercial chemical partner. Access Newswire ](https://www.accessnewswire.com/newsroom/en/biotechnology/successful-pilot-scale-run-with-cayman-chemical-validates-exozymes-technology-and-sca-1148545?ref=nexi.fund) Independent confirmation that cell-free economics pass external scrutiny.